These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 33973194)

  • 21. Passive immune therapies: another tool against COVID-19.
    Estcourt LJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.
    Lung T; Kazatchkine MD; Risch L; Risch M; Nydegger UE
    Transfus Apher Sci; 2020 Oct; 59(5):102936. PubMed ID: 32919880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
    Chen JT; Ostermann M
    Crit Care Clin; 2022 Jul; 38(3):587-600. PubMed ID: 35667745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
    Ali S; Shalim E; Farhan F; Anjum F; Ali A; Uddin SM; Shahab F; Haider M; Ahmed I; Ali MR; Khan S; Rao S; Guriro K; Elahi S; Ali M; Mushtaq T; Sayeed MA; Muhaymin SM; Luxmi S; Saifullah ; Qureshi S
    Trials; 2022 Nov; 23(1):932. PubMed ID: 36348476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic.
    Farcet MR; Karbiener M; Schwaiger J; Ilk R; Kreil TR
    J Infect Dis; 2022 Oct; 226(8):1357-1361. PubMed ID: 33725725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
    Gunjegaonkar SM; Shanmugarajan TS; Arunsundar M; Arjun UVNV; Devi K; Wankhede SB; Ravichandiran V
    Therapie; 2021; 76(4):335-345. PubMed ID: 34238584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019.
    Tang J; Grubbs G; Lee Y; Wu H; Luke TC; Egland KA; Bausch CL; Sullivan EJ; Khurana S
    J Infect Dis; 2022 Sep; 226(4):655-663. PubMed ID: 35106573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
    Bormann M; van de Sand L; Witzke O; Krawczyk A
    Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential pharmacological agents for COVID-19.
    Kotwani A; Gandra S
    Indian J Public Health; 2020 Jun; 64(Supplement):S112-S116. PubMed ID: 32496239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.
    Casadevall A; Joyner MJ; Pirofski LA
    J Clin Invest; 2020 Oct; 130(10):5112-5114. PubMed ID: 32634126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.